Like ASXL1, it was also explored by Guglielmelli in 2011 in an analysis of 370 patients with primary myelofibrosis and 148 with post-PV/post-ET MF, where genotyping for EZH2 identified mutations in 5.9%, 1.2%, and 9.4% of patients with primary MF, post-PV MF and post-ET MF, respectively [65]. This evidence concerns the gene EZH2 and essential thrombocythemia.